Company Filing History:
Years Active: 2003
Title: Anil K Mishra: Innovator in Radiolabeled Peptide Technology
Introduction
Anil K Mishra is a prominent inventor based in Delhi, India. He has made significant contributions to the field of medical imaging and therapy through his innovative work on radiolabeled peptide analogs. His research focuses on the development of agents that can selectively target specific receptors in mammalian systems, enhancing diagnostic and therapeutic capabilities.
Latest Patents
Anil K Mishra holds a patent for "Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy." This invention encompasses radiolabeled peptide analogs of vasoactive intestinal peptide (VIP) that are labeled with a radionuclide. These agents are useful for imaging target sites within living systems. The invention provides radiolabeled VIP derivatives that bind selectively to the VIP receptor on target cells. It relates to the radiolabeling of VIP-receptor specific agents and their use for radiodiagnostic and radiotherapeutic purposes. The methods for radiolabeling these peptides with radionuclides and their application as scintigraphic imaging agents are also included. The radiolabeled VIP derivatives exhibit pharmacological activity, making them valuable for visualizing VIP-receptor positive tumors and metastases, as well as for targeted treatment of such tumors in vivo.
Career Highlights
Anil K Mishra is associated with the Dabur Research Foundation, where he continues to advance his research in peptide technology. His work has implications for improving cancer diagnostics and therapies, showcasing his commitment to enhancing medical science.
Collaborations
Anil has collaborated with notable colleagues such as Anand C Burman and Sudhanand Prasad, contributing to a dynamic research environment that fosters innovation.
Conclusion
Anil K Mishra's contributions to the field of radiolabeled peptide technology highlight his role as a key innovator in medical science. His work not only advances diagnostic techniques but also opens new avenues for targeted cancer therapies.